Compare · MSLE vs NVO
MSLE vs NVO
Side-by-side comparison of Satellos Bioscience Inc. (MSLE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MSLE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 1196.7x MSLE ($145.1M).
- Over the past year, MSLE is down 43.6% and NVO is down 30.4% - NVO leads by 13.2 points.
- MSLE has been more active in the news (4 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for MSLE).
- Company
- Satellos Bioscience Inc.
- Novo Nordisk A/S
- Price
- $6.70-0.89%
- $38.82-1.05%
- Market cap
- $145.1M
- $173.66B
- 1M return
- -30.35%
- -10.14%
- 1Y return
- -43.60%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 3
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MSLE
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Granted Composition of Matter Patent for Forazapadin
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
- SEC Form 6-K filed by Satellos Bioscience Inc.
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos to Present at the 31st Annual Congress of the World Muscle Society
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
- SEC Form 6-K filed by Satellos Bioscience Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank